PA
RYTM icon

Profund Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Profund Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
16,805
-5,982
-26% -$541K 0.05% 212
2026
Q1 		$1.98M Buy
22,787
+1,741
+8% +$169K 0.07% 210
2025
Q4 		$2.25M Buy
21,046
+8,589
+69% +$911K 0.07% 193
2025
Q3 		$1.26M Buy
12,457
+1,203
+11% +$112K 0.04% 277
2025
Q2 		$711K Sell
11,254
-1,190
-10% -$72.9K 0.03% 379
2025
Q1 		$659K Buy
12,444
+1,963
+19% +$109K 0.03% 396
2024
Q4 		$587K Sell
10,481
-2,877
-22% -$159K 0.02% 433
2024
Q3 		$700K Sell
13,358
-617
-4% -$29.6K 0.03% 415
2024
Q2 		$574K Sell
13,975
-20,306
-59% -$811K 0.02% 458
2024
Q1 		$1.49M Buy
34,281
+13,790
+67% +$604K 0.06% 232
2023
Q4 		$942K Sell
20,491
-7,327
-26% -$231K 0.04% 339
2023
Q3 		$638K Sell
27,818
-19,262
-41% -$431K 0.04% 399
2023
Q2 		$776K Buy
47,080
+705
+2% +$12.7K 0.04% 388
2023
Q1 		$827K Buy
+46,375
New +$1.16M 0.05% 352

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Profund Advisors's RYTM Position: Q2 2026 in Review

Profund Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 26% in Q2 2026, selling an estimated $541K and leaving 16,805 shares worth $1.87M. The position accounts for 0.05% of the portfolio, ranked #212.

Profund Advisors first reported a position in RYTM in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.25M in Q4 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Profund Advisors held 16,805 shares of Rhythm Pharmaceuticals worth $1.87M as of Q2 2026.
  • Profund Advisors sold 5,982 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $541K.
  • Rhythm Pharmaceuticals made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #212 holding.
  • Profund Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Rhythm Pharmaceuticals position peaked at $2.25M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.